Prévisions du marché des services de pharmacocinétique au Moyen-Orient et en Afrique jusqu\'en 2031 - Analyse régionale - par type de médicament (petite molécule, grande molécule et vaccins), type de service (études précliniques ADME et humaines, analyse et rapports PK/PD, simulations de dosage, analyse des risques et autres), application thérapeutique (oncologie, maladies infectieuses, troubles neurologiques, maladies auto-immunes, troubles gynécologiques, maladies cardiovasculaires, troubles respiratoires et autres) et utilisateur final (sociétés pharmaceutiques et biotechnologiques, organismes de recherche sous contrat et autres)
La prévalence croissante des maladies chroniques et infectieuses renforce le marché des services pharmacocinétiques au Moyen-Orient et en Afrique
La prévalence croissante de maladies chroniques telles que le diabète, le cancer et les maladies auto-immunes a été l\'un des principaux catalyseurs des efforts de développement de médicaments à travers le monde. Selon les données 2024 de l\'Organisation mondiale de la santé (OMS), environ 422 millions de personnes dans le monde souffrent de diabète, et ces cas se trouvent principalement dans les pays à revenu moyen et faible, provoquant environ 1,5 million de décès chaque année. Les sociétés pharmaceutiques sont à l\'avant-garde du développement de médicaments pour traiter diverses maladies. Les études pharmacocinétiques sont essentielles pour comprendre le comportement de ces médicaments dans le corps d\'un patient en analysant le processus d\'absorption, de distribution, de métabolisation et d\'élimination (ADME) dans le corps humain. L\'absorption d\'un médicament dans la circulation systémique affecte la vitesse et la concentration auxquelles un médicament peut atteindre le site d\'action, par exemple le plasma. Les schémas de distribution du médicament dans l\'organisme varient en fonction de ses propriétés biochimiques et de sa physiologie. Le métabolisme implique la transformation du médicament par l\'organisme en composés ultérieurs. Cette étape est essentielle pour convertir le médicament en substances hydrosolubles afin de les rendre aptes à l\'élimination rénale. Le métabolisme est également important pour la conversion de promédicaments, tels que la codéine, en métabolites actifs. L\'excrétion des médicaments du corps est principalement régie par les reins ; cependant, dans plusieurs cas, les médicaments peuvent être excrétés par les poumons, la peau ou le tractus gastro-intestinal. La dynamique ADME définit la biodisponibilité des médicaments dans le corps, et les doses d\'entretien des médicaments sont calculées en fonction de leurs temps de clairance (concentration plasmatique souhaitée divisée par la biodisponibilité). La compréhension de la clairance permet aux praticiens de calculer les taux de dosage appropriés.
Les études pharmacocinétiques se concentrent sur l\'optimisation des schémas posologiques des médicaments chez les sujets d\'étude pour comprendre l\'efficacité et la sécurité d\'un médicament. Ces études sont essentielles pour garantir la sécurité des médicaments développés pour les traitements à long terme, ce qui permet d\'évaluer l\'adéquation et la stabilité des formulations de médicaments dans la gestion des maladies chroniques. Par conséquent, la charge croissante des maladies chroniques et infectieuses souligne l\'importance des études pharmacocinétiques pour développer des traitements personnalisés sûrs et efficaces.
Aperçu du marché des services de pharmacocinétique au Moyen-Orient et en Afrique
L\'Afrique du Sud représente la plus grande part du marché des services de pharmacocinétique au Moyen-Orient et en Afrique. Le gouvernement sud-africain a commencé à offrir des incitations à l\'investissement, à prendre des mesures pour protéger les droits de propriété intellectuelle (PI), à simplifier les règles fiscales et à imposer de meilleures politiques réglementaires pour attirer les investissements étrangers afin de nourrir à terme le paysage des essais cliniques dans le pays. En 2019, un total d\'environ 62,67 millions de dollars américains (1 milliard de ZAR) a été investi dans les essais à venir et en cours. Entre 2016 et 2021, environ 0,18 milliard USD (2,95 milliards ZAR) ont été dépensés par des sociétés pharmaceutiques multinationales innovantes opérant en Afrique du Sud pour soutenir des activités de recherche clinique axées sur la satisfaction des besoins médicaux non satisfaits du pays.
L\'Afrique du Sud est le pays le plus développé économiquement du continent africain et a établi de meilleures normes réglementaires pour les essais cliniques. La baisse des coûts des opérations de recherche clinique et un risque mineur de litige font de l\'Afrique du Sud une option attrayante pour les entreprises étrangères qui externalisent leurs opérations de recherche clinique. De plus, le nombre d\'essais a augmenté en raison des taux de recrutement élevés et d\'un environnement réglementaire amélioré dans le pays. L\'Afrique du Sud reçoit des parrainages substantiels de sociétés pharmaceutiques innovantes pour mener des recherches cliniques, sans aucun signe de ralentissement. Ainsi, l\'industrie de la recherche clinique en pleine progression soutient la croissance du marché des services de pharmacocinétique dans le pays.
Chiffre d\'affaires et prévisions du marché des services pharmacocinétiques au Moyen-Orient et en Afrique jusqu\'en 2031 (en millions de dollars américains)
Segmentation du marché des services pharmacocinétiques au Moyen-Orient et en Afrique
Le marché des services pharmacocinétiques au Moyen-Orient et en Afrique est classé en type de médicament, type de service, application thérapeutique, utilisateur final et pays.
En fonction du type de médicament, le marché des services pharmacocinétiques au Moyen-Orient et en Afrique est segmenté en petites molécules, grosses molécules et vaccins. Le segment des petites molécules détenait la plus grande part de marché en 2023.
En termes de type de service, le marché des services pharmacocinétiques au Moyen-Orient et en Afrique est classé en études précliniques ADME et humaines, analyses et rapports PK/PD, simulations de dosage, analyses de risques, etc. Français Le segment des études précliniques ADME et humaines détenait la plus grande part de marché en 2023.
Par application thérapeutique, le marché des services de pharmacocinétique du Moyen-Orient et de l\'Afrique est segmenté en oncologie, maladies infectieuses, troubles neurologiques, maladies auto-immunes, troubles gynécologiques, maladies cardiovasculaires, troubles respiratoires et autres. Le segment de l\'oncologie détenait la plus grande part de marché en 2023.
Par utilisateur final, le marché des services de pharmacocinétique du Moyen-Orient et de l\'Afrique est segmenté en sociétés pharmaceutiques et biotechnologiques, organismes de recherche sous contrat et autres. Le segment des organismes de recherche sous contrat détenait la plus grande part de marché en 2023.
Par pays, le marché des services de pharmacocinétique du Moyen-Orient et de l\'Afrique est segmenté en Afrique du Sud, Arabie saoudite, Émirats arabes unis et reste du Moyen-Orient et de l\'Afrique. L\'Afrique du Sud a dominé la part de marché des services de pharmacocinétique du Moyen-Orient et de l\'Afrique en 2023.
Charles River Laboratories International Inc; Eurofins Scientific SE; Certara Inc.; Parexel International Corp; Thermo Fisher Scientific Inc.; Allucent ; PACIFIC BIOLABS ; et SGS SA font partie des principales sociétés opérant sur le marché des services pharmacocinétiques au Moyen-Orient et en Afrique.
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Middle East & Africa Pharmacokinetics Services Market - Key Market Dynamics
4.1 Market Drivers
4.1.1 Rising Prevalence of Chronic and Infectious Diseases
4.1.2 Expanding Range of Application of Pharmacokinetic Studies
4.1.3 Outsourcing of Pharmacokinetics Services to CROs
4.2 Market Restraints
4.2.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries
4.3 Market Opportunities
4.3.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics
4.4 Future Trend
4.4.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services
4.5 Impact of Drivers and Restraints:
5. Pharmacokinetics Services Market - Middle East & Africa Analysis
5.1 Middle East & Africa Pharmacokinetics Services Market Overview
5.2 Middle East & Africa Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
6. Middle East & Africa Pharmacokinetics Services Market Analysis - by Drug Type
6.1 Overview
6.2 Small Molecule
6.2.1 Overview
6.2.2 Small Molecule: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
6.3 Large Molecule
6.3.1 Overview
6.3.2 Large Molecule: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
6.4 Vaccines
6.4.1 Overview
6.4.2 Vaccines: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7. Middle East & Africa Pharmacokinetics Services Market Analysis - by Service Type
7.1 Overview
7.2 Pre-Clinical ADME and Human Studies
7.2.1 Overview
7.2.2 Pre-Clinical ADME and Human Studies: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.3 PK/PD Analysis and Reporting
7.3.1 Overview
7.3.2 PK/PD Analysis and Reporting: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Dosing Simulations
7.4.1 Overview
7.4.2 Dosing Simulations: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.5 Risk Analysis
7.5.1 Overview
7.5.2 Risk Analysis: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8. Middle East & Africa Pharmacokinetics Services Market Analysis - by Therapeutic Application
8.1 Oncology
8.1.1 Overview
8.1.2 Oncology: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Infectious Diseases
8.2.1 Overview
8.2.2 Infectious Diseases: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Neurological Disorders
8.3.1 Overview
8.3.2 Neurological Disorders: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Autoimmune Diseases
8.4.1 Overview
8.4.2 Autoimmune Diseases: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.5 Gynecological Disorders
8.5.1 Overview
8.5.2 Gynecological Disorders: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.6 Cardiovascular Diseases
8.6.1 Overview
8.6.2 Cardiovascular Diseases: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.7 Respiratory Disorders
8.7.1 Overview
8.7.2 Respiratory Disorders: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9. Middle East & Africa Pharmacokinetics Services Market Analysis - by End User
9.1 Pharmaceutical and Biotechnology Companies
9.1.1 Overview
9.1.2 Pharmaceutical and Biotechnology Companies: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Contract Research Organization
9.2.1 Overview
9.2.2 Contract Research Organization: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Others
9.3.1 Overview
9.3.2 Others: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10. Middle East & Africa Pharmacokinetics Services Market - Country Analysis
10.1 Middle East and Africa
10.1.1 Middle East & Africa Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
10.1.1.1 Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.1.1 Overview
10.1.1.1.2 Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.1.3 Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.1.4 Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.1.5 Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.1.6 Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market Breakdown, by End User
10.1.1.2 South Africa: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.2.1 Overview
10.1.1.2.2 South Africa: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.2.3 South Africa: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.2.4 South Africa: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.2.5 South Africa: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.2.6 South Africa: Middle East & Africa Pharmacokinetics Services Market Breakdown, by End User
10.1.1.3 United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.3.1 Overview
10.1.1.3.2 United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.3.3 United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.3.4 United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.3.5 United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.3.6 United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market Breakdown, by End User
10.1.1.4 Rest of Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.4.1 Overview
10.1.1.4.2 Rest of Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.4.3 Rest of Middle East & Africa Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.4.4 Rest of Middle East & Africa Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.4.5 Rest of Middle East & Africa Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.4.6 Rest of Middle East & Africa Pharmacokinetics Services Market Breakdown, by End User
11. Company Profile
11.1 Charles River Laboratories International Inc
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Eurofins Scientific SE
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Certara Inc.
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.4 Parexel International Corp
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Thermo Fisher Scientific Inc.
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Allucent
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 PACIFIC BIOLABS
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 SGS SA
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
12. Appendix
12.1 About The Insight Partners
12.2 Glossary of Terms for Pharmacokinetic Services Market
?
List of Tables
Table 1. Middle East & Africa Pharmacokinetics Services Market Segmentation
Table 2. Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Drug Type
Table 3. Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Service Type
Table 4. Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Therapeutic Application
Table 5. Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by End User
Table 6. South Africa: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Drug Type
Table 7. South Africa: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Service Type
Table 8. South Africa: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Therapeutic Application
Table 9. South Africa: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by End User
Table 10. United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Drug Type
Table 11. United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Service Type
Table 12. United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Therapeutic Application
Table 13. United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by End User
Table 14. Rest of Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Drug Type
Table 15. Rest of Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Service Type
Table 16. Rest of Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Therapeutic Application
Table 17. Rest of Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by End User
Table 18. Glossary of Terms
?
List of Figures
Figure 1. Middle East & Africa Pharmacokinetics Services Market Segmentation, by Country
Figure 2. Middle East & Africa Pharmacokinetics Services Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Middle East & Africa Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
Figure 5. Middle East & Africa Pharmacokinetics Services Market Share (%) - by Drug Type (2023 and 2031)
Figure 6. Small Molecule: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 7. Large Molecule: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 8. Vaccines: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 9. Middle East & Africa Pharmacokinetics Services Market Share (%) - by Service Type (2023 and 2031)
Figure 10. Pre-Clinical ADME and Human Studies: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 11. PK/PD Analysis and Reporting: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 12. Dosing Simulations: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 13. Risk Analysis: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 14. Others: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 15. Middle East & Africa Pharmacokinetics Services Market Share (%) - by Therapeutic Application (2023 and 2031)
Figure 16. Oncology: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 17. Infectious Diseases: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 18. Neurological Disorders: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 19. Autoimmune Diseases: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 20. Gynecological Disorders: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 21. Cardiovascular Diseases: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 22. Respiratory Disorders: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 23. Others: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 24. Middle East & Africa Pharmacokinetics Services Market Share (%) - by End User (2023 and 2031)
Figure 25. Pharmaceutical and Biotechnology Companies: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 26. Contract Research Organization: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 27. Others: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 28. Middle East & Africa Pharmacokinetics Services Market by Key Countries - Revenue 2023 (US$ Million)
Figure 29. Middle East & Africa Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 30. Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million)
Figure 31. South Africa: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million)
Figure 32. United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million)
Figure 33. Rest of Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million)
- Allucent
- Certara Inc.
- Charles River Laboratories International Inc
- Eurofins Scientific SE
- PACIFIC BIOLABS
- Parexel International Corp
- SGS SA
- Thermo Fisher Scientific Inc.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa pharmacokinetics services market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa pharmacokinetics services market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Middle East & Africa pharmacokinetics services market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.